Which factors help to determine the long-term response to first-line tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma: A Turkish multi-centre study.

Autor:	Majidova N; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey., Seyyar M; Department of Internal Medicine, Division of Medical Oncology, Kocaeli University, Kocaeli, Turkey., Bayraktar DI; Department of Internal Medicine, Division of Medical Oncology, Ondokuz Mayıs University Faculty of Medicine, Samsun, Turkey., Dinç G; Department of Internal Medicine, Division of Medical Oncology, Professor Dr Cemil Tascioglu City Hospital, Istanbul, Turkey., İsgandarov E; Department of Internal Medicine, Division of Medical Oncology, Ondokuz Mayıs University Faculty of Medicine, Samsun, Turkey., Huseynov J; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey., Yaşar A; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey., Çelebi A; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey., Sever N; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey., Kocaaslan E; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey., Erel P; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey., Ağyol Y; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey., Güren AK; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey., Arıkan R; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey., Işık S; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey., Ercelep Ö; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey., Demirağ G; Department of Internal Medicine, Division of Medical Oncology, Ondokuz Mayıs University Faculty of Medicine, Samsun, Turkey., Kefeli U; Department of Internal Medicine, Division of Medical Oncology, Kocaeli University, Kocaeli, Turkey., Köstek O; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey., Bayoğlu İV; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey., Sarı M; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey.
Jazyk:	angličtina
Zdroj:	Biomolecules & biomedicine [Biomol Biomed] 2024 Oct 17; Vol. 24 (6), pp. 1776-1784. Date of Electronic Publication: 2024 Oct 17.
DOI:	10.17305/bb.2024.10512
Abstrakt:	Many developing countries lack access to recommended first-line treatments for metastatic renal cell carcinoma (mRCC), such as immune checkpoint inhibitors (ICIs) or ICI-tyrosine kinase inhibitor (TKI) combinations. As a result, predictive markers are necessary to identify patients who may benefit from single-agent TKIs for long-term response. This study aims to identify such parameters. This was a multi-centre, retrospective study of patients with mRCC who were undergoing first-line treatment with sunitinib or pazopanib. Patients who had been diagnosed with mRCC and had not experienced disease progression for 36 months or more were deemed to have achieved a long-term response. Predictive clinical and pathological characteristics of patients who did not experience long-term disease progression were investigated. A total of 320 patients from four hospitals were included in the study. The median age of the patients was 60 years (range 20-89 years). According to the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk classification, 109 patients were classified as having favourable risk and 211 were in the intermediate-poor risk group. The median progression-free survival (PFS) and overall survival (OS) for all patients were 12.5 months and 76.4 months, respectively. In the long-term responder's group, the median PFS was 78.4 months. Among all patients, prior nephrectomy, the Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) <1, and the absence of brain metastasis were predictive factors for long-term response. For patients in the favourable risk group, the lack of brain metastasis was a predictor of long-term response. In the intermediate-poor risk group, prior nephrectomy and ECOG PS <1 were predictive factors for long-term response. Some individuals with mRCC may experience a durable response to TKIs. The likelihood of a long-term response can be determined by factors such as nephrectomy, ECOG PS < 1, and the absence of brain metastases.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu